Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

479
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
479

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
Same author

Delayed gastric emptying after robot-assisted pancreatoduodenectomy: the Transatlantic Robot Pancreas Consortium (TROPANC).

Surgical endoscopy·2026
Same author

Cigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2026
Same author

Primary retroperitoneal pseudomyxoma masquerading as a benign retroperitoneal abscess from an ascending colon subacute perforation: a case report.

International journal of surgery case reports·2026
Same author

A Biomarker Panel for the Detection of Pancreatic Cancer.

Cancers·2026
Same author

Impact of Surgical Approach on Post-Pancreatoduodenectomy Bleeding: A Multi-Center Analysis.

Annals of surgery·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
08:12

Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique

Published on: February 2, 2022

2.8K

Neoadjuvant Therapy for Localized Pancreatic Cancer.

Jordan McKean1, Patrick Underwood1, Abdul Qahar K Yasinzai2

  • 1Department of Surgery, Division of Surgical Oncology, University of Florida, Gainesville, FL 32608, USA.

Cancers
|March 28, 2026
PubMed
Summary
This summary is machine-generated.

Neoadjuvant therapy for pancreatic cancer shows promise in improving surgery and chemotherapy delivery. However, survival benefits are inconsistent, especially for resectable cases, necessitating further research.

Keywords:
chemotherapyneoadjuvant therapypancreatic cancer

More Related Videos

Laparoscopic Radical Antegrade Modular Pancreatosplenectomy via Dorsal-Caudal Artery Approach for Pancreatic Neck-Body Cancer
12:07

Laparoscopic Radical Antegrade Modular Pancreatosplenectomy via Dorsal-Caudal Artery Approach for Pancreatic Neck-Body Cancer

Published on: November 18, 2022

4.8K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

13.1K

Related Experiment Videos

Last Updated: Mar 29, 2026

Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
08:12

Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique

Published on: February 2, 2022

2.8K
Laparoscopic Radical Antegrade Modular Pancreatosplenectomy via Dorsal-Caudal Artery Approach for Pancreatic Neck-Body Cancer
12:07

Laparoscopic Radical Antegrade Modular Pancreatosplenectomy via Dorsal-Caudal Artery Approach for Pancreatic Neck-Body Cancer

Published on: November 18, 2022

4.8K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

13.1K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is aggressive with poor survival.
  • Standard care involves surgery plus adjuvant chemotherapy, but many patients don't complete it.
  • Neoadjuvant therapy offers a strategy to improve systemic therapy delivery and resection rates.

Purpose of the Study:

  • To review clinical trials on neoadjuvant therapy for resectable and borderline resectable pancreatic cancer.
  • To compare neoadjuvant approaches against upfront surgery.
  • To evaluate different neoadjuvant chemotherapy regimens and the addition of radiation therapy.

Main Methods:

  • Narrative review of randomized and phase II-III clinical trials.
  • Focus on comparative studies of neoadjuvant vs. upfront surgery.
  • Inclusion of ongoing phase III trials.

Main Results:

  • Neoadjuvant therapy improved chemotherapy delivery and R0 resection rates.
  • Some studies showed survival benefits, particularly in borderline resectable PDAC (mOS 15.7-37 months).
  • Survival advantages over upfront surgery were not consistently demonstrated, especially in resectable PDAC.

Conclusions:

  • Neoadjuvant therapy is feasible and safe for localized pancreatic cancer.
  • Survival benefits remain inconsistent, particularly for resectable disease.
  • Further research, including large randomized trials and improved patient selection, is needed.